Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assayArticle Published on 2022-11-012022-11-15 Journal: Diagnostic microbiology and infectious disease [Category] SARS, 진단, 치료기술, [키워드] Abbott anti-spike antibodies anti-spike antibody antibody Antibody test Antibody titer appear approved Architect assist benefit CMIA correlated strongly COVID-19 detect effective feasible female IgM/IgG immune response Immune status immunoassay individual IQR Lateral lateral flow lateral flow assay log-linear regression median age Microparticle monoclonal antibody monoclonal antibody therapy monoclonal antibody treatment natural infection participant Patient Prophylaxis SARS-CoV-2 SARS-CoV-2 IgG sera seronegative patient Severe COVID-19 Infection tested therapy Treatment undergo vaccination [DOI] 10.1016/j.diagmicrobio.2022.115788 PMC 바로가기
Antibody response after COVID-19 vaccination in intravenous immunoglobulin-treated immune neuropathiesArticle Published on 2022-11-012022-11-15 Journal: European journal of neurology [Category] SARS, 진단, [키워드] Administered administration age Alter analyzed anti-SARS-CoV-2 anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG antibodies COVID-19 COVID-19 vaccination COVID-19 vaccine decrease dose enzyme-linked immunosorbent female healthy subjects IgA IgA titer IgG IgG titer IgM immune immunoassay Immunoglobulin impair indicate Interaction intravenous Intravenous immunoglobulin IVIG Microparticle mRNA vaccine observation Patient positive Prevalence reduce remained sera serological response serum serum titer significantly subsequent the antibody response therapeutic vaccination Vaccine vaccine dose vaccine interaction. [DOI] 10.1111/ene.15508 PMC 바로가기
A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccineArticle Published on 2022-11-012022-11-15 Journal: Translational research : the journal of laboratory [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] activated airway epithelial cells Antigen B cell Beta Cell cross-reactive delta variant dendritic cell development domain effective elicited facilitated humoral IgA response immune response Immunity induce Inflammation intranasal long-lasting lung mice Microparticle mucosal nasal Parenteral porous prime and boost Protective RBD SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 vaccine subunit type 1 helper vaccination Vaccinations Vaccine variant Viral load [DOI] 10.1016/j.trsl.2022.06.004 PMC 바로가기
Antibody response after two doses of homologous or heterologous SARS-CoV-2 vaccines in healthcare workers at health promotion centers: A prospective observational study건강증진센터 의료 종사자를 대상으로 동종 또는 이종 SARS-CoV-2 백신 2회 접종 후 항체 반응: 전향적 관찰 연구Observational Study Published on 2022-10-012022-09-12 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] Abbott Diagnostics acute respiratory syndrome affecting anti-SARS-CoV-2 anti-spike-protein receptor-binding domain (S-RBD) antibodies antibody chemiluminescence coronavirus coronavirus disease COVID-19 determine domain dose Factor female first dose HCW HCWs Health healthcare healthcare worker Healthcare workers Heterologous highest homologous homologous or heterologous identify IgG level immune immunoassay individuals Linear regression analysis Messenger RNA Microparticle mRNA mRNA vaccine mRNA vaccines multivariable participant prospective observational study recruited S-RBD SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 IgG SARS-CoV-2 vaccine second dose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines Sex significantly significantly higher tested the antibody response vaccination Vaccine Viral vector vaccine Viral vector vaccines were measured [DOI] 10.1002/jmv.27911 PMC 바로가기 [Article Type] Observational Study
Affinity of anti-spike antibodies to three major SARS-CoV-2 variants in recipients of three major vaccines Research Published on 2022-08-252022-10-05 Journal: Communications Medicine [Category] 진단, [키워드] ACE2 adaptive affinity Anti-spike anti-spike antibody anti-viral antibody antibody apparent affinity approach binding blocking blood plasma COVID-19 Delta determine develop domain epitope human serum humoral immune response Immunity immunogenic Infection interfere janssen Microparticle Microscope Moderna offer omicron Pfizer Pfizer/BioNTech Protein Quantitative RBD recipient reduced Result SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 variant SARS-CoV-2 virus serum the RBD the spike protein Vaccine vaccine-induced antibody Vaccines variants variety virus [DOI] 10.1038/s43856-022-00174-9 [Article Type] Research
One-Year Sustained Cellular and Humoral Immunities in Coronavirus Disease 2019 (COVID-19) Convalescents코로나바이러스 질병 2019(COVID-19) 회복기의 1년 지속 세포 및 체액 면역Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, 치료기술, 치료법, [키워드] antibodies antibody Antigen Asymptomatic cellular chemiluminescence immunoassay circulating cohort study conducted convalescent COVID-19 cytokine detectable disease disease onset disease severity ELISA ELISPOT enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay enzyme-linked immunospot assay feature flow cytometry Humoral immunity IgG antibodies IgM IgM antibody immune immune memory Immunity Immunoglobulin individual intracellular cytokine staining membrane memory Microparticle Mild moderate N proteins neutralization neutralizing antibody nucleocapsid protein Nucleocapsid proteins positive SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2-specific antibodies SARS-CoV-2-specific IgG SARS-CoV-2-specific T-cell response severe disease specific antibodies specific IgG antibodies T cells T-cell T-cell responses the SARS-CoV-2 was tested were assessed [DOI] 10.1093/cid/ciab884 PMC 바로가기 [Article Type] Article
Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults뉴질랜드 성인에서 BNT162b2 COVID-19 백신의 면역원성Article Published on 2022-08-122022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] age All participant All participants analysed anti-S IgG Antibody Response baseline Beta BMI BNT162b2 BNT162b2 mRNA vaccine BNT162b2 vaccine Cellular immune response cellular immune responses co-morbidities Cohort COVID-19 COVID-19 disease COVID-19 vaccine declined Delta diabete diabetes diabetics disease dose enrichment Ethnic groups female Gender General population IgG immune response immune responses immunoassay immunogenicity in vitro International Lower Māori median age Microparticle morbidities morbidity naïve neutralise neutralising antibody neutralising response neutralising responses neutralizing capacity New obesity of BNT162b2 Older Older adults omicron other variant other variants Pacific Islander Population prospective cohort study pulmonary disease Quantitative recipient representation response risk robust SARS-CoV-2 vaccine second dose second vaccination serious COVID-19 seroconverted serum sample serum samples strain the vaccine Vaccine variant Viral viral neutralisation Wuhan [DOI] 10.1016/j.vaccine.2022.07.009 PMC 바로가기 [Article Type] Article
Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients혈액학적 환자에서 anti-SARS-CoV-2 mRNA 백신접종에 대한 혈청학적 반응 평가Article Published on 2022-08-082022-09-12 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] Administered anti-SARS-CoV-2 anti-SARS-CoV-2 IgG anti-SARS-CoV-2 vaccination Anti-spike anti-Spike IgG anti-spike IgG level antibody Antibody titer association Cell Cohort cohort of patient Concentration control arm control group Cutoff demographic variable difference drug Effect evaluated greater health worker healthy healthy subjects hematological Hematological malignancies Hematological malignancy heterogeneous highest identify IgG IgG titer immune system immunoassay Immunocompromised patients Immunosuppression implication inhibitor Italy leukemia Microparticle molecular mRNA mRNA vaccination mRNA vaccine onco-hematology. parameter pathology Patient patients performed Predictive reached reduced reported SARS-CoV-2 SARS-CoV-2 antibody second dose seroconversion rate serological response shown significantly lower spike IgG statistical significance steroid stratified Surveillance the mean the patient Therapies therapy treated tyrosine underlying disease vaccination Vaccine was reduced [DOI] 10.3389/fimmu.2022.892331 PMC 바로가기 [Article Type] Article
Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease종양 괴사 인자-α 길항제의 사용은 염증성 장 질환이 있는 백신 접종 환자에서 SARS-CoV-2에 대한 약화된 IgG 항체 반응과 관련이 있습니다Observational Study Published on 2022-07-052022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] Against age antagonist antagonists anti-SARS-CoV-2 antibody anti-SARS-CoV-2 vaccination antibody Antibody concentrations Antibody titer Antibody titers Biologicals Blood blood sampling bowel Characteristics clinical Clinical characteristics Combination completion Concentration COVID-19 Crohn's disease defined demonstrated detectable disease Effect elapsed geometric geometric mean IBD IgG IgG antibodies IgG antibody IgG antibody titer IgG antibody titers immune response immunoassay immunomodulating Immunosuppressive medication immunosuppressive medications increased risk independent independent of Inflammatory Inflammatory bowel disease medication Microparticle monotherapy Most patients mRNA mRNA vaccines mRNA-based vaccine mRNA-based vaccines Multivariable models Patient patient age patients patients treated prospective observational cohort quantitative determination RBD receive receiving Receptor-binding domain regimen response S1 subunit sampling SARS-CoV-2 SARS-COV-2 infection Seroconversion serological response significantly lower Spike protein the receptor-binding domain the S1 subunit the spike protein titer TNF-α-antagonists treated Treatment Tumor ulcerative colitis vaccination Vaccine vector was used were measured were recorded [DOI] 10.3389/fimmu.2022.920333 PMC 바로가기 [Article Type] Observational Study
Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care CenterSARS-CoV-2 감염 후 혈청전환율 및 ChAdOx1-nCOV COVISHIELD™ 또는 BBV-152 COVAXIN™ 백신 2회 접종 후 신장 동종이식 환자: 2개의 공립 및 사립 3차 치료 센터 경험Article Published on 2022-06-302022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] anti- SARS-CoV-2 antibody anti-SARS-CoV-2 antibody formation Antibody titer appear center chemiluminescence COVAXIN™ COVISHIELDTM dose effective elevated evaluated experience high mortality humoral Humoral immunity IgG immunoassay Immunocompromised induce Infection median Microparticle Mortality natural infection Neutralizing antibody titer on type Private Public Rate recipient reported response robust SARS-CoV-2 SARS-COV-2 infection Seroconversion seroconversion rate serum Spike protein Tertiary the SARS-CoV-2 Transplant vaccination Vaccine Vaccines was measured [DOI] 10.3389/fimmu.2022.911738 PMC 바로가기 [Article Type] Article